Compare TSAT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | GYRE |
|---|---|---|
| Founded | 1969 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 573.4M |
| IPO Year | 2021 | 2004 |
| Metric | TSAT | GYRE |
|---|---|---|
| Price | $48.47 | $6.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $37.00 | $17.00 |
| AVG Volume (30 Days) | ★ 281.7K | 88.0K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.77 | $5.44 |
| 52 Week High | $59.12 | $9.42 |
| Indicator | TSAT | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 44.30 |
| Support Level | $45.56 | $5.44 |
| Resistance Level | $56.88 | $8.13 |
| Average True Range (ATR) | 4.89 | 0.32 |
| MACD | -1.12 | 0.06 |
| Stochastic Oscillator | 39.69 | 53.69 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.